Skip to main content
KARD
NASDAQ Life Sciences

Perceptive Advisors Discloses 8.9% Stake in Kardigan Post-IPO

Analysis by Wiseek AI
Sentiment info
Neutral
Importance info
7
Price
$22.58
Mkt Cap
0
52W Low
$20.07
52W High
$24.86
52W Position info
13% above low
Off High info
9.2% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

KARD is trading near its 52-week low of $20.07 (13% above the low).

Summary

Perceptive Advisors, a major institutional investor, has disclosed an 8.9% ownership stake in Kardigan, Inc. following the company's recent IPO, stemming from the conversion of preferred shares.


Key Events · Ownership and Investor Activity · KARD

  • Significant Ownership Stake Disclosed

    Perceptive Advisors LLC and its affiliates, including Joseph Edelman, reported beneficial ownership of 8,254,144 shares of Kardigan, Inc. common stock, representing 8.9% of the company's outstanding shares.

  • Post-IPO Conversion

    The stake primarily resulted from the automatic conversion of Series A Convertible Redeemable Preferred Stock into common stock on June 17, 2026, in connection with Kardigan's Initial Public Offering.

  • Board Representation and Lock-up

    Douglas Giordano, a Managing Director at Perceptive Advisors, serves on Kardigan's board of directors. The reporting persons also entered into a 180-day lock-up agreement, restricting sales of their shares post-IPO.


Analysis · KARD · Life Sciences

This initial Schedule 13D filing reveals that Perceptive Advisors and its affiliated entities, including Joseph Edelman, hold a significant 8.9% stake in Kardigan, Inc. following its recent Initial Public Offering. The shares were acquired through the automatic conversion of preferred stock into common stock upon the IPO. This disclosure provides transparency into a major institutional investor's position and influence, especially given that a managing director from Perceptive Advisors serves on Kardigan's board.

At the time of this filing, KARD was trading at $22.58 on NASDAQ in the Life Sciences sector. The 52-week trading range was $20.07 to $24.86. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KARD - Latest Insights

KARD
Jun 29, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $25.90
Real-time Price: $25.90 info
Change: $0 (0%) info
Market Cap: N/A info
KARD
Jun 25, 2026, 4:00 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $22.58
Real-time Price: $25.90 info
Change: +$3.32 (+15%) info
Market Cap: N/A info
KARD
Jun 23, 2026, 6:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.78
Real-time Price: $25.90 info
Change: +$3.12 (+14%) info
Market Cap: N/A info
KARD
Jun 18, 2026, 5:14 PM EDT
Filing Type: 424B4
Importance Score:
9
Price at Filing: $20.43
Real-time Price: $25.90 info
Change: +$5.47 (+27%) info
Market Cap: N/A info
KARD
Jun 18, 2026, 4:21 PM EDT
Source: Binance News
Importance Score:
9
Price at Filing: $22.00
Real-time Price: $25.90 info
Change: +$3.90 (+18%) info
Market Cap: N/A info
KARD
Jun 18, 2026, 12:42 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $17.72
Real-time Price: $25.90 info
Change: +$8.18 (+46%) info
Market Cap: N/A info
KARD
Jun 18, 2026, 5:06 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: N/A
Real-time Price: $25.90 info
Change: N/A info
Market Cap: N/A info
KARD
Jun 17, 2026, 9:18 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: N/A
Real-time Price: $25.90 info
Change: N/A info
Market Cap: N/A info